Omeros Co. (NASDAQ:OMER) Shares Acquired by Picton Mahoney Asset Management

Picton Mahoney Asset Management raised its holdings in shares of Omeros Co. (NASDAQ:OMER) by 692.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,040 shares of the biopharmaceutical company’s stock after purchasing an additional 4,404 shares during the period. Picton Mahoney Asset Management’s holdings in Omeros were worth $50,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in OMER. Truvestments Capital LLC increased its position in shares of Omeros by 116.5% during the fourth quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 1,669 shares in the last quarter. BNP Paribas Financial Markets increased its position in shares of Omeros by 130.6% during the third quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 7,016 shares in the last quarter. MML Investors Services LLC increased its position in shares of Omeros by 19.2% during the third quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock worth $74,000 after purchasing an additional 3,000 shares in the last quarter. US Bancorp DE acquired a new position in shares of Omeros during the fourth quarter worth $81,000. Finally, China Universal Asset Management Co. Ltd. acquired a new position in shares of Omeros during the fourth quarter worth $121,000. 48.79% of the stock is owned by institutional investors and hedge funds.

Omeros Stock Performance

NASDAQ:OMER opened at $8.42 on Monday. Omeros Co. has a one year low of $2.61 and a one year high of $13.60. The firm has a market cap of $487.94 million, a price-to-earnings ratio of -3.65 and a beta of 2.03. The firm’s fifty day moving average is $8.80 and its two-hundred day moving average is $7.20.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on OMER shares. Needham & Company LLC reissued a “hold” rating on shares of Omeros in a research report on Friday, January 17th. StockNews.com raised Omeros from a “sell” rating to a “hold” rating in a research report on Thursday. Finally, D. Boral Capital reissued a “buy” rating and issued a $36.00 target price on shares of Omeros in a research report on Thursday, February 20th. Three research analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $22.50.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.